Products Sativex + Placebo
Sativex + Placebo Approved Completed 🔥 Hot Multiple Sclerosis, Spasticity
Jan 1, 2012 → May 1, 2013
About Sativex + Placebo Sativex + Placebo is a approved stage product being developed by Jazz Pharmaceuticals for Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01964547. Target conditions include Multiple Sclerosis, Spasticity.
Clinical Trials (7) NCT ID Phase Status Start Completion Indication NCT01812616 Phase 1/2 Completed Sep 1, 2014 Jun 1, 2016 Cancer NCT01898520 Phase 3 Completed Dec 1, 2013 Mar 1, 2017 Cerebral Palsy NCT01964547 Approved Completed Jan 1, 2012 May 1, 2013 Multiple Sclerosis NCT00702468 Phase 3 Completed Nov 1, 2007 Jan 1, 2009 Spasticity NCT00710554 Phase 3 Completed Aug 1, 2005 Oct 1, 2006 Pain NCT00710424 Phase 3 Completed Jul 1, 2005 Jun 1, 2006 Pain NCT01599234 Phase 3 Completed Mar 1, 2005 Dec 1, 2005 Multiple Sclerosis
Product Company Stage Hype Score Placebo + Pirtobrutinib Eli Lilly Phase 2 Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 NEX-20A Nanexa AB Phase 1 agenT-797 MiNK Therapeutics Phase 1 Duloxetine Hydrochloride (HCI) + Placebo Eli Lilly Phase 3 Temferon Genenta Science Phase 1/2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 CT-P53 + US-Ocrevus + EU-Ocrevus Celltrion Phase 3 CS-0777 tablets + CS-0777 tablets + CS-0777 tablets Daiichi Sankyo Phase 1 ASP7487, Velcade, Dexamethasone Astellas Pharma Phase 1/2 PHE885 Novartis Phase 2 Mirabegron + Placebo Astellas Pharma Approved Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo Astellas Pharma Approved Denileukin Diftitox (Ontak) Eisai Phase 1 Palonosetron Eisai Phase 2 BIW-8962 Kyowa Kirin Phase 1 KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor) Kyowa Kirin Phase 2 KW-2478 + Bortezomib Kyowa Kirin Phase 1/2 ONO-2808 + Placebo Ono Pharmaceutical Phase 2 KW-2478 Kyowa Kirin Phase 1
Other Products from Jazz Pharmaceuticals